Department of Anesthesiology, Affiliated Hospital of Yangzhou University, Yangzhou, 225000, China.
Graduate School of Dalian Medical University, Dalian, 116000, China.
BMC Anesthesiol. 2023 Dec 1;23(1):395. doi: 10.1186/s12871-023-02350-3.
Thoracoscopic surgical techniques continue to advance, yet the intensity of postoperative pain remains significant, impeding swift patient recovery. This study aimed to evaluate the differences in postoperative pain and recuperation between patients receiving intrathecal morphine paired with low-dose bupivacaine and those administered general anesthesia exclusively.
This randomized controlled trial enrolled 100 patients, who were allocated into three groups: Group M (5 μg/kg morphine intrathecal injection), Group B (5 μg/kg morphine combined with bupivacaine 3 mg intrathecal injection) and Group C (intrathecal sham injection). The primary outcome was the assessment of pain relief using the Numeric Rating Scale (NRS). Additionally, intraoperative remifentanil consumption was quantified at the end of the surgery, and postoperative opioid use was determined by the number of patient-controlled analgesia (PCIA) compressions at 48 h post-surgery. Both the efficacy of the treatments and any complications were meticulously recorded.
Postoperative NRS scores for both rest and exercise at 6, 12, 24, and 48 h were significantly lower in groups M and B than in group C (P<0.05). The intraoperative remifentanil dosage was significantly greater in groups M and C than in group B (P<0.05), while there was no significant difference between groups M and C (P>0.05). There was no significant difference in intraoperative propofol dosage across all three groups (P>0.05). Postoperative dosages of both sufentanil and Nonsteroidal anti-inflammatory drugs (NSAIDs) were significantly less in groups M and B compared to group C (P<0.05). The time of first analgesic request was later in both groups M and B than in group C (P<0.05). Specific and total scores were elevated at 2 days postoperative when compared to scores at 1 day for all groups (P<0.05). Furthermore, at 1 day and 2 days postoperatively, both specific scores and total scores were higher in groups M and B compared to group C (P<0.05).
Intrathecal administration of morphine combined with bupivacaine has been shown to effectively ameliorate acute pain in patients undergoing thoracoscopic surgery.
The trial was registered on ClinicalTrials.gov: ChiCTR2200058544, registered 10/04/2022.
胸腔镜手术技术不断发展,但术后疼痛强度仍然显著,阻碍了患者的快速康复。本研究旨在评估鞘内注射吗啡联合小剂量布比卡因与单纯全身麻醉在术后疼痛和恢复方面的差异。
这是一项随机对照试验,纳入了 100 名患者,将其分为三组:M 组(鞘内注射 5μg/kg 吗啡)、B 组(鞘内注射 5μg/kg 吗啡联合布比卡因 3mg)和 C 组(鞘内假注射)。主要结局是使用数字评分量表(NRS)评估疼痛缓解情况。此外,还在手术结束时量化术中瑞芬太尼的消耗,并通过术后 48 小时患者自控镇痛(PCIA)按压次数确定术后阿片类药物的使用。详细记录治疗效果和任何并发症。
M 组和 B 组在术后 6、12、24 和 48 小时静息和运动时的 NRS 评分均显著低于 C 组(P<0.05)。M 组和 C 组的术中瑞芬太尼剂量明显大于 B 组(P<0.05),而 M 组和 C 组之间无显著差异(P>0.05)。三组之间术中丙泊酚剂量无显著差异(P>0.05)。M 组和 B 组术后舒芬太尼和非甾体抗炎药(NSAIDs)的用量明显少于 C 组(P<0.05)。M 组和 B 组首次要求镇痛的时间晚于 C 组(P<0.05)。与术后第 1 天相比,所有组在术后第 2 天的特定和总评分均升高(P<0.05)。此外,与 C 组相比,M 组和 B 组在术后第 1 天和第 2 天的特定评分和总评分均较高(P<0.05)。
鞘内注射吗啡联合布比卡因可有效改善胸腔镜手术后患者的急性疼痛。
该试验在 ClinicalTrials.gov 上注册:ChiCTR2200058544,注册日期为 2022 年 10 月 4 日。